Welcome!

News Feed Item

MediPoint: Biopsy Devices - EU Analysis and Market Forecasts

LONDON, April 22, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

MediPoint: Biopsy Devices - EU Analysis and Market Forecasts

http://www.reportbuyer.com/pharma_healthcare/diagnostics/medipoint_biopsy_devices_eu_analysis_market_forecasts.html

MediPoint: Biopsy Devices - EU Analysis and Market Forecasts

Summary

Cancer is the uncontrolled growth of abnormal cells in the body. It can affect numerous organs and tissues of the body. When a patient is suspected of having a particular type of cancer, a biopsy procedure is performed to extract a target tissue sample for histological analysis. This intervention typically provides a definitive cancer diagnosis for the patient. Given that these procedures play such an important role in the diagnostic pathway for various cancers, medical device manufacturers have worked to develop biopsy devices that maximize the volume and quality of the tissue samples, as well as decrease their negative impact on the patient's body. As seen with other medical device markets, less invasive biopsy techniques have entered the market and have established a new gold standard in many global regions.

While there are significant barriers facing this market, current and future players can still position themselves to obtain a competitive advantage. The major European countries included in this forecast have general mass screening programs for breast cancer detection and they will be increasing their adoption of more expensive VAB devices. Additionally, the emerging economies will see an increased shift from fine needle aspiration devices to more expensive core biopsy devices over the forecast.

Scope

- An overview of biopsy devices, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized EU biopsy devices market revenue and future forecasts from 2010 to 2012, forecast for 7 years to 2019.
- Investigation of current and future market competition for biopsy devices
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the biopsy devices sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL).

Reasons to buy

- Understand the trends shaping and driving EU biopsy devices Market.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in EU biopsy devices market through 2019.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What's the next big thing in EU biopsy devices market landscape? Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 10
1.2 List of Figures 12
2 Introduction 14
2.1 Overview 14
2.2 Catalyst 15
2.3 Related Reports 15
3 Industry Overview 16
3.1 Types of Biopsies 16
3.1.1 Surgical Biopsy 16
3.1.2 Fine Needle Aspiration 16
3.1.3 Core Needle Biopsy 17
3.1.4 Vacuum-Assisted Biopsy 18
3.2 Biopsy Procedure Trends 18
3.2.1 EU 18
3.3 Market Access to Cancer Screening Programs 24
3.3.1 Regulation 24
3.3.2 Biopsy Device Adoption Patterns 27
3.3.3 Reimbursement Trends 31
3.4 Regulatory Issues/Recalls 33
3.5 Mergers & Acquisitions/Key Partnerships 34
3.5.1 Hologic Acquires Suros Surgical Systems 34
3.5.2 C. R. Bard Acquires SenoRx 34
3.5.3 Devicor Medical Products Acquires Breast Care Portfolio from Ethicon Endo-Surgery 34
3.6 Economic Impact of Cancer Screening and Treatment 35
3.7 Additional Indications for Biopsy Devices 36
4 Unmet Needs 37
4.1 Overview 37
4.2 More Efficient Screening Tests for Prostate Cancer 37
4.3 More Efficient Screening Tests for Breast Cancer 38
4.4 More Efficient Screening Guidelines for Thyroid Cancer 38
4.5 Screening Tests That Can Provide Histological Analysis In Situ 39
5 Market Opportunity Analysis 40
5.1 Increase Marketing for Vacuum-Assisted Biopsy Devices in European Countries 40
5.2 Bundling Solutions 41
5.3 Focus Efforts on China's Increasing Adoption of VAB Devices 42
5.4 Market for Prostate Cancer Screening Coverage in Europe 42
6 Market Drivers and Barriers 44
6.1 Market Drivers 44
6.1.1 Inadequate Screening Tests for Particular Cancers 44
6.1.2 Demand for Minimally-Invasive Biopsy Techniques 45
6.1.3 Increased Adherence to Certain Cancer Screening Guidelines 45
6.1.4 Aging Patient Population 46
6.2 Market Barriers 47
6.2.1 Increased Competition from Other Cancer Diagnostic Tests 47
6.2.2 Breast Biopsy Reimbursement Bundling 50
6.2.3 Decreased Adherence to Certain Cancer Screening Guidelines 52
6.2.4 Benefits of Mass Prostate Cancer Screening Being Outweighed by Risks 53
7 Competitive Assessment 55
7.1 Overview 55
7.2 Classification Based on System 55
7.2.1 Vacuum-Assisted Biopsy Devices 55
7.2.2 Core Needle Biopsy Devices 57
7.2.3 Fine Needle Aspiration Devices 58
8 Pipeline Assessment 60
8.1 Overview 60
8.1.1 Optical Biopsy 61
8.1.2 Liquid Biopsy 62
9 Clinical Trial Analysis 63
10 Current and Future Players 65
10.1 Trends in Corporate Strategy 65
10.2 Company Profiles 65
10.2.1 Argon Medical Devices 65
10.2.2 Boston Scientific 68
10.2.3 Cardinal Health 71
10.2.4 CareFusion Corporation 72
10.2.5 Cook Medical 74
10.2.6 C. R. Bard 77
10.2.7 Devicor Medical Products 83
10.2.8 DTR Medical 87
10.2.9 Gallini Medical Devices 88
10.2.10 Hologic 91
10.2.11 INRAD 94
10.2.12 Intact Medical Corporation 96
10.2.13 TSK Laboratory 98
11 Market Outlook 100
11.1 Company Market Share 100
11.1.1 Vacuum-Assisted Biopsy Market Share 100
11.1.2 Core Needle Biopsy/Fine Needle Aspiration Market Share 102
11.2 By Segment 103
11.2.1 Fine Needle Aspiration 103
11.2.2 Core Needle Biopsy 104
11.2.3 Vacuum-Assisted Biopsy 105
11.3 By Geography 106
11.3.1 France 106
11.3.2 Germany 107
11.3.3 Italy 109
11.3.4 Spain 110
11.3.5 United Kingdom 112
12 Appendix 114
12.1 Bibliography 114
12.2 Abbreviations 123
12.3 Report Methodology 125
12.3.1 Overview 125
12.3.2 Coverage 125
12.3.3 Primary Research 125
12.3.4 Secondary Research 126
12.3.5 Forecasting Methodology 127
12.4 Key Opinion Leaders Included in This Study 127
12.5 About the Authors 128
12.5.1 Joseph A. Gregory, Analyst, Surgical Devices 128
12.5.2 Derek Archila, MBA, Director of Research and Analysis, Medical Devices 128
12.6 Global Head of Healthcare 129
12.6.1 Bonnie Bain, Ph.D., Global Head of Healthcare 129
12.7 About MediPoint 130
12.8 About GlobalData 130
12.9 Disclaimer 130

List of Tables

Table 1: Breast Cancer Incidence Rates, 5EU, 2010-2019 21
Table 2: Biopsy Device Adoption Patterns in Diagnosing Prostate Cancer, Global, 2013 and 2019 28
Table 3: Biopsy Device Adoption Patterns in Diagnosing Breast Cancer, Global, 2013 and 2019 29
Table 4: Biopsy Device Adoption Patterns in Diagnosing Lung Cancer, Global, 2013 and 2019 30
Table 5: Biopsy Device Adoption Patterns in Diagnosing Liver Cancer, Global, 2013 and 2019 30
Table 6: Biopsy Device Adoption Patterns in Diagnosing Thyroid Cancer, Global, 2013 and 2019 31
Table 7: Age Demographics, Age >65 Years, Global, 2013 46
Table 8: Stereotactic Breast Biopsy Ambulatory Surgery Center Billing, 2011 51
Table 9: Stereotactic Breast Biopsy Physician Billing, 2011 51
Table 10: Company Profile - Argon Medical Devices 66
Table 11: Product Portfolio - Argon Medical Devices 67
Table 12: Argon Medical Devices, SWOT Analysis, 2013 67
Table 13: Company Profile - Boston Scientific 68
Table 14: Product Portfolio - Boston Scientific 70
Table 15: Boston Scientific SWOT Analysis, 2013 70
Table 16: Company Profile - Cardinal Health 71
Table 17: Product Portfolio - Cardinal Health 72
Table 18: Cardinal Health SWOT Analysis, 2013 72
Table 19: Company Profile - CareFusion Corporation 73
Table 20: Product Portfolio - CareFusion 74
Table 21: CareFusion, SWOT Analysis, 2013 74
Table 22: Company Profile - Cook Medical 75
Table 23: Product Portfolio - Cook Medical 76
Table 24: Cook Medical, SWOT Analysis, 2013 77
Table 25: Company Profile - C. R. Bard 78
Table 26: Product Portfolio - C. R. Bard 78
Table 27: C.R. Bard, SWOT Analysis, 2013 82
Table 28: Company Profile - Devicor Medical Products 83
Table 29: Product Portfolio - Devicor Medical Products 86
Table 30: Devicor Medical Products SWOT Analysis, 2013 86
Table 31: Company Profile - DTR Medical 87
Table 32: Product Portfolio - DTR Medical 87
Table 33: DTR Medical SWOT Analysis, 2013 88
Table 34: Company Profile - Gallini Medical Devices 89
Table 35: Product Portfolio - Gallini Medical Devices 90
Table 36: Gallini Medical Devices SWOT Analysis, 2013 90
Table 37: Company Profile - Hologic 91
Table 38: Product Portfolio - Hologic 93
Table 39: Hologic SWOT Analysis, 2013 93
Table 40: Company Profile - INRAD 94
Table 41: Product Portfolio - INRAD 95
Table 42: INRAD SWOT Analysis, 2013 95
Table 43: Company Profile - Intact Medical Corporation 96
Table 44: Product Portfolio - Intact Medical Corporation 97
Table 45: Intact Medical Corporation SWOT Analysis, 2013 97
Table 46: Company Profile - TSK Laboratory 98
Table 47: Product Portfolio - TSK Laboratory 99
Table 48: TSK Laboratory SWOT Analysis, 2013 99
Table 49: VAB, Global Market Share, 2013 101
Table 50: CNB/FNA, Global Market Share, 2013 102
Table 51: EU FNA Device Sales ($m) Forecast, 2010-2019 103
Table 52: EU CNB Device Sales ($m) Forecast, 2010-2019 104
Table 53: EU VAB Device Sales ($m) Forecast, 2010-2019 105
Table 54: France Biopsy Devices Sales ($m) Forecast, 2010-2019 106
Table 55: Germany Biopsy Devices Sales ($m) Forecast, 2010-2019 108
Table 56: Italy Biopsy Devices Sales ($m) Forecast, 2010-2019 109
Table 57: Spain Biopsy Devices Sales ($m) Forecast, 2010-2019 111
Table 58: United Kingdom Biopsy Devices Sales ($m) Forecast, 2010-2019 112

List of Figures

Figure 1: Biopsy Procedure Volumes: Prostate, 5EU, 2010-2019 19
Figure 2: Biopsy Procedure Volumes: Breast, 5EU, 2010-2019 20
Figure 3: Biopsy Procedure Volumes: Lung, 5EU, 2010-2019 22
Figure 4: Biopsy Procedure Volumes: Liver, 5EU, 2010-2019 23
Figure 5: Biopsy Procedure Volumes: Thyroid, 5EU, 2010-2019 24
Figure 6: EnCor Breast Biopsy System 79
Figure 7: EnCor Enspire Breast Biopsy System 80
Figure 8: EnCor Ultra Breast Biopsy System 80
Figure 9: Finesse Ultra Breast Biopsy System 81
Figure 10: Vacora Breast Biopsy System 82
Figure 11: Original Mammotome System 84
Figure 12: Mammotome Elite 85
Figure 13: Mammotome Revolve 86
Figure 14: VAB, Global Market Share, 2013 101
Figure 15: CNB/FNA, Global Market Share, 2013 102
Figure 16: EU FNA Device Sales ($m) Forecast, 2010-2019 103
Figure 17: EU CNB Device Sales ($m) Forecast, 2010-2019 104
Figure 18: EU VAB Device Sales ($m) Forecast, 2010-2019 105
Figure 19: France Biopsy Devices Sales ($) Forecast, 2010-2019 107
Figure 20: Germany Biopsy Devices Sales ($) Forecast, 2010-2019 108
Figure 21: Italy Biopsy Devices Sales ($) Forecast, 2010-2019 110
Figure 22: Spain Biopsy Devices Sales ($) Forecast, 2010-2019 111
Figure 23: United Kingdom Biopsy Devices Sales ($) Forecast, 2010-2019 113

Read the full report:
MediPoint: Biopsy Devices - EU Analysis and Market Forecasts

http://www.reportbuyer.com/pharma_healthcare/diagnostics/medipoint_biopsy_devices_eu_analysis_market_forecasts.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Digital transformation is about embracing digital technologies into a company's culture to better connect with its customers, automate processes, create better tools, enter new markets, etc. Such a transformation requires continuous orchestration across teams and an environment based on open collaboration and daily experiments. In his session at 21st Cloud Expo, Alex Casalboni, Technical (Cloud) Evangelist at Cloud Academy, explored and discussed the most urgent unsolved challenges to achieve f...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
There is a huge demand for responsive, real-time mobile and web experiences, but current architectural patterns do not easily accommodate applications that respond to events in real time. Common solutions using message queues or HTTP long-polling quickly lead to resiliency, scalability and development velocity challenges. In his session at 21st Cloud Expo, Ryland Degnan, a Senior Software Engineer on the Netflix Edge Platform team, will discuss how by leveraging a reactive stream-based protocol,...
"I focus on what we are calling CAST Highlight, which is our SaaS application portfolio analysis tool. It is an extremely lightweight tool that can integrate with pretty much any build process right now," explained Andrew Siegmund, Application Migration Specialist for CAST, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that Evatronix will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Evatronix SA offers comprehensive solutions in the design and implementation of electronic systems, in CAD / CAM deployment, and also is a designer and manufacturer of advanced 3D scanners for professional applications.
SYS-CON Events announced today that Synametrics Technologies will exhibit at SYS-CON's 22nd International Cloud Expo®, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Synametrics Technologies is a privately held company based in Plainsboro, New Jersey that has been providing solutions for the developer community since 1997. Based on the success of its initial product offerings such as WinSQL, Xeams, SynaMan and Syncrify, Synametrics continues to create and hone inn...
As many know, the first generation of Cloud Management Platform (CMP) solutions were designed for managing virtual infrastructure (IaaS) and traditional applications. But that's no longer enough to satisfy evolving and complex business requirements. In his session at 21st Cloud Expo, Scott Davis, Embotics CTO, explored how next-generation CMPs ensure organizations can manage cloud-native and microservice-based application architectures, while also facilitating agile DevOps methodology. He expla...
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. In his session at @BigDataExpo, Jack Norris, Senior Vice President, Data and Applications at MapR Technologies, reviewed best practices to ...
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
DevOps promotes continuous improvement through a culture of collaboration. But in real terms, how do you: Integrate activities across diverse teams and services? Make objective decisions with system-wide visibility? Use feedback loops to enable learning and improvement? With technology insights and real-world examples, in his general session at @DevOpsSummit, at 21st Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, explored how leading organizations use data-driven DevOps to close th...
Digital Transformation (DX) is not a "one-size-fits all" strategy. Each organization needs to develop its own unique, long-term DX plan. It must do so by realizing that we now live in a data-driven age, and that technologies such as Cloud Computing, Big Data, the IoT, Cognitive Computing, and Blockchain are only tools. In her general session at 21st Cloud Expo, Rebecca Wanta explained how the strategy must focus on DX and include a commitment from top management to create great IT jobs, monitor ...
"WineSOFT is a software company making proxy server software, which is widely used in the telecommunication industry or the content delivery networks or e-commerce," explained Jonathan Ahn, COO of WineSOFT, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
No hype cycles or predictions of a gazillion things here. IoT is here. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, an Associate Partner of Analytics, IoT & Cybersecurity at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He also discussed the evaluation of communication standards and IoT messaging protocols, data...
Recently, WebRTC has a lot of eyes from market. The use cases of WebRTC are expanding - video chat, online education, online health care etc. Not only for human-to-human communication, but also IoT use cases such as machine to human use cases can be seen recently. One of the typical use-case is remote camera monitoring. With WebRTC, people can have interoperability and flexibility for deploying monitoring service. However, the benefit of WebRTC for IoT is not only its convenience and interopera...
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...